| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000539 |
Purpose
To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.
| Condition | Intervention | Phase |
|
Arterial Occlusive Diseases Cardiovascular Diseases Heart Diseases Vascular Diseases Diabetes Mellitus |
Drug: niacin Drug: pravastatin Drug: beta-carotene Drug: vitamin E Behavioral: dietary supplements Drug: vitamin C Drug: warfarin |
Phase III |
| MedlinePlus related topics: | Diabetes Dietary Supplements Heart Diseases Vascular Diseases |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized |
| Study Start Date: | September 1992 |
| Estimated Study Completion Date: | March 1999 |
 |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Men and women with symptomatic or asymptomatic peripheral arterial disease.
Contacts and Locations More Information
| Study ID Numbers: | 82 |
| First Received: | October 27, 1999 |
| Last Updated: | January 10, 2006 |
| ClinicalTrials.gov Identifier: | NCT00000539 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
